265 related articles for article (PubMed ID: 17535926)
1. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.
DiNapoli JM; Kotelkin A; Yang L; Elankumaran S; Murphy BR; Samal SK; Collins PL; Bukreyev A
Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9788-93. PubMed ID: 17535926
[TBL] [Abstract][Full Text] [Related]
2. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.
Bukreyev A; Huang Z; Yang L; Elankumaran S; St Claire M; Murphy BR; Samal SK; Collins PL
J Virol; 2005 Nov; 79(21):13275-84. PubMed ID: 16227250
[TBL] [Abstract][Full Text] [Related]
3. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
Buchholz UJ; Bukreyev A; Yang L; Lamirande EW; Murphy BR; Subbarao K; Collins PL
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9804-9. PubMed ID: 15210961
[TBL] [Abstract][Full Text] [Related]
4. Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.
DiNapoli JM; Ward JM; Cheng L; Yang L; Elankumaran S; Murphy BR; Samal SK; Collins PL; Bukreyev A
Vaccine; 2009 Mar; 27(10):1530-9. PubMed ID: 19168110
[TBL] [Abstract][Full Text] [Related]
5. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
Bukreyev A; Lamirande EW; Buchholz UJ; Vogel LN; Elkins WR; St Claire M; Murphy BR; Subbarao K; Collins PL
Lancet; 2004 Jun; 363(9427):2122-7. PubMed ID: 15220033
[TBL] [Abstract][Full Text] [Related]
6. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate.
Sun W; Leist SR; McCroskery S; Liu Y; Slamanig S; Oliva J; Amanat F; Schäfer A; Dinnon KH; García-Sastre A; Krammer F; Baric RS; Palese P
EBioMedicine; 2020 Dec; 62():103132. PubMed ID: 33232870
[TBL] [Abstract][Full Text] [Related]
7. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate.
Sun W; Leist SR; McCroskery S; Liu Y; Slamanig S; Oliva J; Amanat F; Schäfer A; Dinnon KH; García-Sastre A; Krammer F; Baric RS; Palese P
bioRxiv; 2020 Jul; ():. PubMed ID: 32743571
[TBL] [Abstract][Full Text] [Related]
8. Heterologous prime-boost immunization of Newcastle disease virus vectored vaccines protected broiler chickens against highly pathogenic avian influenza and Newcastle disease viruses.
Kim SH; Samal SK
Vaccine; 2017 Jul; 35(33):4133-4139. PubMed ID: 28668574
[TBL] [Abstract][Full Text] [Related]
9. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.
DiNapoli JM; Nayak B; Yang L; Finneyfrock BW; Cook A; Andersen H; Torres-Velez F; Murphy BR; Samal SK; Collins PL; Bukreyev A
J Virol; 2010 Feb; 84(3):1489-503. PubMed ID: 19923177
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
[TBL] [Abstract][Full Text] [Related]
11. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters.
Liu X; Luongo C; Matsuoka Y; Park HS; Santos C; Yang L; Moore IN; Afroz S; Johnson RF; Lafont BAP; Martens C; Best SM; Munster VJ; Hollý J; Yewdell JW; Le Nouën C; Munir S; Buchholz UJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34876520
[TBL] [Abstract][Full Text] [Related]
12. Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).
Suresh MR; Bhatnagar PK; Das D
J Pharm Pharm Sci; 2008 Apr; 11(2):1s-13s. PubMed ID: 19203466
[TBL] [Abstract][Full Text] [Related]
13. Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein.
Zhi Y; Kobinger GP; Jordan H; Suchma K; Weiss SR; Shen H; Schumer G; Gao G; Boyer JL; Crystal RG; Wilson JM
Virology; 2005 Apr; 335(1):34-45. PubMed ID: 15823604
[TBL] [Abstract][Full Text] [Related]
14. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.
DiNapoli JM; Yang L; Suguitan A; Elankumaran S; Dorward DW; Murphy BR; Samal SK; Collins PL; Bukreyev A
J Virol; 2007 Nov; 81(21):11560-8. PubMed ID: 17715243
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of avian paramyxovirus serotypes 2 to 10 as vaccine vectors in chickens previously immunized against Newcastle disease virus.
Tsunekuni R; Hikono H; Saito T
Vet Immunol Immunopathol; 2014 Aug; 160(3-4):184-91. PubMed ID: 24880702
[TBL] [Abstract][Full Text] [Related]
16. A recombinant Newcastle disease virus (NDV) expressing infectious laryngotracheitis virus (ILTV) surface glycoprotein D protects against highly virulent ILTV and NDV challenges in chickens.
Kanabagatte Basavarajappa M; Kumar S; Khattar SK; Gebreluul GT; Paldurai A; Samal SK
Vaccine; 2014 Jun; 32(28):3555-63. PubMed ID: 24793943
[TBL] [Abstract][Full Text] [Related]
17. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.
Qin E; Shi H; Tang L; Wang C; Chang G; Ding Z; Zhao K; Wang J; Chen Z; Yu M; Si B; Liu J; Wu D; Cheng X; Yang B; Peng W; Meng Q; Liu B; Han W; Yin X; Duan H; Zhan D; Tian L; Li S; Wu J; Tan G; Li Y; Li Y; Liu Y; Liu H; Lv F; Zhang Y; Kong X; Fan B; Jiang T; Xu S; Wang X; Li C; Wu X; Deng Y; Zhao M; Zhu Q
Vaccine; 2006 Feb; 24(7):1028-34. PubMed ID: 16388880
[TBL] [Abstract][Full Text] [Related]
19. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.
Kapadia SU; Simon ID; Rose JK
Virology; 2008 Jun; 376(1):165-72. PubMed ID: 18396306
[TBL] [Abstract][Full Text] [Related]
20. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.
DiNapoli JM; Yang L; Samal SK; Murphy BR; Collins PL; Bukreyev A
Vaccine; 2010 Dec; 29(1):17-25. PubMed ID: 21034822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
